Genome-Wide/NN
Association/NN
Study/NN
of/IN
Orthostatic/JJ
Hypotension/NN
and/CC
Supine-Standing/JJ
Blood/NN
Pressure/NN
Changes/NNS
in/IN
Two/CD
Korean/JJ
Populations/NNS
./.
====================
Orthostatic/JJ
hypotension/NN
(/(
OH/NN
)/)
is/VBZ
defined/VBN
by/IN
a/DT
20-mm/JJ
Hg/JJ
difference/NN
of/IN
systolic/JJ
blood/NN
pressure/NN
(/(
dtSBP/NN
)/)
and/or/CC
a/DT
10-mm/JJ
Hg/JJ
difference/NN
of/IN
diastolic/JJ
blood/NN
pressure/NN
(/(
dtDBP/NN
)/)
between/IN
supine/NN
and/CC
standing/VBG
,/,
and/CC
OH/NN
is/VBZ
associated/VBN
with/IN
a/DT
failure/NN
of/IN
the/DT
cardiovascular/JJ
reflex/NN
to/TO
maintain/VB
blood/NN
pressure/NN
on/IN
standing/VBG
from/IN
a/DT
supine/NN
position/NN
./.
====================
To/TO
understand/VB
the/DT
underlying/VBG
genetic/JJ
factors/NNS
for/IN
OH/NN
traits/VBZ
(/(
OH/NN
,/,
dtSBP/NN
,/,
and/CC
dtDBP/NN
)/)
,/,
genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
using/VBG
333,651/CD
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
were/VBD
conducted/VBN
separately/RB
for/IN
two/CD
population-based/JJ
cohorts/NNS
,/,
Ansung/JJ
(/(
n/NN
=/JJ
3,173/CD
)/)
and/CC
Ansan/NN
(/(
n/NN
=/JJ
3,255/CD
)/)
./.
====================
We/PRP
identified/VBD
8/CD
SNPs/NNS
(/(
5/CD
SNPs/NNS
for/IN
dtSBP/NN
and/CC
3/CD
SNPs/NNS
for/IN
dtDBP/NN
)/)
that/WDT
were/VBD
repeatedly/RB
associated/VBN
in/IN
both/DT
the/DT
Ansung/JJ
and/CC
Ansan/NN
cohorts/NNS
and/CC
had/VBD
p-values/NNS
of/IN
</JJR
1/CD
×/NN
10-5/CD
in/IN
the/DT
meta-analysis/NN
./.
====================
Unfortunately/RB
,/,
the/DT
SNPs/NNS
of/IN
the/DT
OH/NN
case/NN
control/NN
GWAS/NN
did/VBD
not/RB
pass/VB
our/PRP$
p-value/NN
criteria/NNS
./.
====================
Four/CD
of/IN
8/CD
SNPs/NNS
were/VBD
located/JJ
in/IN
the/DT
intergenic/JJ
region/NN
of/IN
chromosome/NN
2/CD
,/,
and/CC
the/DT
nearest/JJ
gene/NN
(/(
CTNNA2/NN
)/)
was/VBD
located/JJ
at/IN
1/CD
Mb/NN
of/IN
distance/NN
./.
====================
CTNNA2/NN
is/VBZ
a/DT
linker/NN
between/IN
cadherin/NN
adhesion/NN
receptors/NNS
and/CC
the/DT
actin/NN
cytoskeleton/JJ
and/CC
is/VBZ
essential/JJ
for/IN
stabilizing/VBG
dendritic/JJ
spines/NNS
in/IN
rodent/JJ
hippocampal/JJ
neurons/NNS
./.
====================
Although/IN
there/EX
is/VBZ
no/DT
report/NN
about/IN
the/DT
function/NN
in/IN
blood/NN
pressure/NN
regulation/NN
,/,
hippocampal/JJ
neurons/NNS
interact/VBP
primarily/RB
with/IN
the/DT
autonomic/JJ
nervous/JJ
system/NN
and/CC
might/MD
be/VB
related/JJ
to/TO
OH/NN
./.
====================
The/DT
remaining/VBG
SNPs/NNS
,/,
rs7098785/NN
of/IN
dtSBP/NN
trait/VBP
and/CC
rs6892553/NN
,/,
rs16887217/RB
,/,
and/CC
rs4959677/NN
of/IN
dtDBP/NN
trait/VBP
were/VBD
located/JJ
in/IN
the/DT
PIK3AP1/NN
intron/NN
,/,
ACTBL2-3/NN
'/``
flanking/JJ
,/,
STAR/NN
intron/NN
,/,
and/CC
intergenic/JJ
region/NN
,/,
respectively/RB
,/,
but/CC
there/EX
was/VBD
no/DT
clear/JJ
functional/JJ
link/NN
to/TO
blood/NN
pressure/NN
regulation/NN
./.
====================
Orthostasis/NN
causes/VBZ
a/DT
gravitational/JJ
shift/NN
in/IN
circulating/VBG
blood/NN
from/IN
the/DT
intra-thoracic/JJ
space/NN
to/TO
lower/JJR
extremities/NNS
and/CC
reduces/VBZ
venous/JJ
return/NN
to/TO
the/DT
heart/NN
./.
====================
This/DT
transient/JJ
increase/NN
in/IN
sympathetic/JJ
tone/NN
and/CC
decrease/NN
in/IN
parasympathetic/JJ
tone/NN
and/CC
these/DT
normal/JJ
cardiovascular/JJ
reflexes/NNS
cause/VBP
an/DT
increase/NN
in/IN
heart/NN
rate/NN
and/CC
vascular/JJ
resistance/NN
,/,
restoring/VBG
normal/JJ
blood/NN
pressure/NN
(/(
BP/NN
)/)
and/CC
cardiac/JJ
output/RB
[/(
1/CD
]/)
./.
====================
Orthostatic/JJ
hypotension/NN
(/(
OH/NN
)/)
is/VBZ
the/DT
failure/NN
of/IN
the/DT
cardiovascular/JJ
reflexes/NNS
to/TO
maintain/VB
BP/NN
on/IN
standing/VBG
from/IN
a/DT
supine/NN
position/NN
[/(
2/CD
]/)
./.
====================
The/DT
Malmö/JJ
Preventive/JJ
Project/JJ
reported/VBD
that/IN
individuals/NNS
with/IN
OH/NN
had/VBD
significantly/RB
increased/VBD
all-cause/RB
mortality/NN
(/(
hazard/JJ
ratio/NN
,/,
1.4/CD
to/TO
1.6/CD
)/)
[/(
3/CD
]/)
./.
====================
OH/NN
has/VBZ
been/VBN
defined/VBN
by/IN
the/DT
international/JJ
consensus/NN
as/IN
a/DT
decrease/NN
in/IN
systolic/JJ
BP/NN
≥/CD
20/CD
mm/NN
Hg/NN
and/or/CC
a/DT
decrease/NN
in/IN
diastolic/JJ
BP/NN
≥/CD
10/CD
mm/NN
Hg/NN
within/IN
3/CD
mintues/NNS
of/IN
standing/VBG
[/(
4/CD
]/)
./.
====================
The/DT
prevalence/NN
of/IN
OH/NN
varies/VBZ
from/IN
5/CD
%/NN
to/TO
30/CD
%/NN
,/,
depending/VBG
greatly/RB
on/IN
the/DT
population/NN
being/VBG
studied/VBN
[/(
5-7/CD
]/)
./.
====================
Aging/NN
is/VBZ
associated/VBN
with/IN
a/DT
definite/JJ
increase/VBP
in/IN
the/DT
prevalence/NN
of/IN
OH/NN
and/CC
was/VBD
reviewed/VBN
in/IN
Benvenuto/NN
and/CC
Krakoff/JJ
[/(
2/CD
]/)
./.
====================
In/IN
addition/NN
to/TO
the/DT
aging/NN
effects/NNS
,/,
OH/NN
is/VBZ
more/RBR
prevalent/JJ
in/IN
hypertensive/JJ
[/(
8/CD
,/,
9/CD
]/)
,/,
neurological/JJ
[/(
10/CD
]/)
,/,
and/CC
diabetic/JJ
patients/NNS
[/(
11/CD
,/,
12/CD
]/)
./.
====================
The/DT
all-cause/JJ
mortality/NN
rate/NN
was/VBD
higher/JJR
in/IN
patients/NNS
with/IN
OH/NN
than/IN
in/IN
those/DT
without/IN
OH/NN
[/(
6/CD
,/,
7/CD
]/)
====================
We/PRP
have/VBP
been/VBN
conducting/VBG
an/DT
epidemiology/NN
study/NN
of/IN
OH/NN
as/IN
part/NN
of/IN
the/DT
Korean/JJ
Genome/NNP
and/CC
Epidemiology/JJ
Study/NN
(/(
KoGES/NN
)/)
and/CC
previously/RB
reported/VBN
that/IN
middle-aged/JJ
adults/NNS
(/(
40-70/CD
years/NNS
)/)
,/,
enrolled/JJ
from/IN
2001/CD
to/TO
2002/CD
,/,
had/VBD
a/DT
12.3/CD
%/NN
overall/JJ
prevalence/NN
of/IN
OH/NN
and/CC
that/IN
the/DT
OH/NN
frequency/NN
increased/VBD
significantly/RB
with/IN
age/NN
,/,
from/IN
6.4/CD
%/NN
in/IN
those/DT
aged/JJ
40-44/CD
years/NNS
to/TO
23.1/CD
%/NN
in/IN
those/DT
aged/JJ
65-69/CD
(/(
p/NN
</JJR
0.001/CD
)/)
[/(
9/CD
]/)
./.
====================
In/IN
addition/NN
,/,
the/DT
study/NN
confirmed/VBD
the/DT
correlations/NNS
between/IN
OH/NN
and/CC
hypertension/NN
,/,
body/NN
mass/NN
index/NN
(/(
BMI/NN
)/)
,/,
and/CC
type/NN
2/CD
diabetes/NNS
[/(
9/CD
]/)
./.
====================
The/DT
genetic/JJ
contribution/NN
to/TO
OH/NN
can/MD
be/VB
hypothesized/VBN
that/IN
the/DT
frequency/NN
of/IN
OH/NN
in/IN
families/NNS
with/IN
a/DT
history/JJ
of/IN
essential/JJ
hypertension/NN
is/VBZ
higher/JJR
than/IN
in/IN
the/DT
general/JJ
population/NN
[/(
4/CD
]/)
./.
====================
A/DT
genetic/JJ
association/NN
study/NN
was/VBD
conducted/VBN
by/IN
Luo/NN
et/FW
al/JJ
./.
====================
[/(
13/CD
]/)
,/,
and/CC
they/PRP
identified/VBD
a/DT
functional/JJ
variant/JJ
of/IN
NEDD4L/NN
(/(
epithelial/JJ
sodium/NN
channel/NN
E3-ubiquitin/NN
ligase/NN
)/)
./.
====================
To/TO
identify/VB
genetic/JJ
factors/NNS
associated/VBN
with/IN
OH/NN
trait/VBP
in/IN
Koreans/NNS
,/,
we/PRP
conducted/VBD
genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
for/IN
OH/NN
case/NN
controls/VBZ
using/VBG
genome-wide/JJ
single/JJ
nucleotide/NN
polymorphism/NN
(/(
SNP/NN
)/)
genotypes/NNS
and/CC
also/RB
tested/VBN
supine/NN
and/CC
standing/VBG
BPs/NNS
as/IN
quantitative/JJ
traits/VBZ
./.
====================
Study/NN
subjects/NNS
====================
The/DT
study/NN
subjects/NNS
consisted/VBD
of/IN
two/CD
population-based/JJ
cohorts/NNS
,/,
Ansung/JJ
and/CC
Ansan/NN
,/,
which/WDT
have/VBP
been/VBN
conducted/VBN
as/IN
part/NN
of/IN
the/DT
KoGES/NN
./.
====================
The/DT
phenotype/NN
of/IN
the/DT
cohort/NN
population/NN
was/VBD
previously/RB
described/VBN
[/(
14/CD
]/)
./.
====================
Briefly/RB
,/,
the/DT
subjects/NNS
came/VBD
from/IN
the/DT
Ansung/JJ
and/CC
Ansan/NN
cities/NNS
,/,
located/JJ
in/IN
Gyeonggi-do/NN
province/NN
near/JJ
Seoul/JJ
,/,
Korea/NN
./.
====================
Written/RB
informed/VBN
consent/NN
was/VBD
obtained/VBN
from/IN
all/DT
participants/NNS
,/,
and/CC
this/DT
research/NN
project/VB
was/VBD
approved/VBN
by/IN
the/DT
institutional/JJ
review/NN
board/IN
in/IN
the/DT
Korea/NN
National/JJ
Institute/JJ
of/IN
Health/NN
(/(
KNIH/NN
)/)
./.
====================
Subjects/NNS
with/IN
genotype/NN
accuracies/VBZ
below/IN
98/CD
%/NN
and/CC
high/JJ
missing/VBG
genotype/NN
call/JJ
rates/NNS
(/(
≥4/CD
%/NN
)/)
,/,
high/JJ
heterozygosity/NN
(/(
>/JJR
30/CD
%/NN
)/)
,/,
or/CC
inconsistency/NN
in/IN
sex/NN
were/VBD
excluded/VBN
from/IN
subsequent/JJ
analyses/NNS
./.
====================
Individuals/NNS
who/WP
had/VBD
a/DT
tumor/NN
were/VBD
excluded/VBN
,/,
as/IN
were/VBD
related/JJ
individuals/NNS
whose/WP$
estimated/VBN
identity-by-state/VBP
values/NNS
were/VBD
high/JJ
(/(
>/JJR
0.80/CD
)/)
./.
====================
After/IN
these/DT
quality/NN
control/NN
steps/NNS
,/,
8,842/CD
samples/NNS
were/VBD
selected/VBN
./.
====================
Clinical/JJ
characteristics/NNS
====================
BP/NN
was/VBD
measured/VBN
3/CD
times/NNS
in/IN
the/DT
supine/NN
position/NN
./.
====================
Before/IN
the/DT
first/JJ
measurement/NN
,/,
participants/NNS
rested/VBD
for/IN
5/CD
minutes/NNS
,/,
and/CC
the/DT
3/CD
measurements/NNS
were/VBD
taken/VBN
in/IN
one/CD
arm/NN
showing/VBG
the/DT
higher/JJR
BP/NN
at/IN
least/JJS
3/CD
minutes/NNS
apart/VBP
./.
====================
After/IN
the/DT
supine/NN
position/NN
measurement/NN
,/,
the/DT
BP/NN
was/VBD
measured/VBN
soon/RB
after/IN
standing/VBG
./.
====================
Two/CD
of/IN
8,842/CD
subjects/NNS
did/VBD
not/RB
undergo/VB
BP/NN
measurement/NN
in/IN
the/DT
standing/NN
posture/JJ
./.
====================
Also/RB
,/,
1,291/CD
individuals/NNS
who/WP
had/VBD
been/VBN
treated/VBN
with/IN
anti-hypertensive/JJ
drug/NN
therapy/NN
and/CC
1,114/NN
self-reported/JJ
diabetic/JJ
patients/NNS
or/CC
diagnosed/VBN
diabetic/JJ
patients/NNS
by/IN
KoGES/NN
were/VBD
excluded/VBN
./.
====================
Ultimately/RB
,/,
3,255/CD
individuals/NNS
from/IN
Ansan/NN
and/CC
3,173/CD
individuals/NNS
from/IN
Ansung/JJ
were/VBD
used/VBN
for/IN
the/DT
GWASs/NNS
./.
====================
Other/JJ
cardiovascular/JJ
risk/NN
factors/NNS
,/,
such/JJ
as/IN
cholesterol/NN
level/NN
and/CC
fasting/JJ
glucose/NN
level/NN
,/,
were/VBD
measured/VBN
from/IN
blood/NN
samples/NNS
after/IN
overnight/JJ
fasting/JJ
./.
====================
Study/NN
genotypes/NNS
====================
The/DT
genotyping/JJ
of/IN
the/DT
cohort/NN
population/NN
was/VBD
previously/RB
described/VBN
for/IN
the/DT
Korea/NN
Associated/VBN
Resource/NN
(/(
KARE/NN
)/)
study/NN
[/(
14/CD
]/)
./.
====================
Most/JJS
DNA/NN
samples/NNS
were/VBD
isolated/VBN
from/IN
the/DT
peripheral/JJ
blood/NN
of/IN
participants/NNS
and/CC
genotyped/VBD
using/VBG
the/DT
Affymetrix/JJ
Genomewide/NN
Human/JJ
SNP/NN
array/NN
5.0/CD
(/(
Affymetrix/JJ
,/,
Inc./NNP
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
The/DT
quality/NN
control/NN
steps/NNS
of/IN
genotypes/NNS
have/VBP
been/VBN
described/VBN
elsewhere/VBP
[/(
14/CD
]/)
./.
====================
Briefly/RB
,/,
the/DT
accuracy/NN
of/IN
the/DT
genotyping/VBG
was/VBD
determined/VBN
by/IN
Bayesian/JJ
Robust/NNP
Linear/JJ
Modeling/JJ
using/VBG
the/DT
Mahalanobis/NN
Distance/NN
(/(
BRLMM/NN
)/)
genotyping/VBG
algorithm/NN
[/(
15/CD
]/)
./.
====================
Consequently/RB
,/,
333,651/CD
SNPs/NNS
had/VBD
a/DT
missing/JJ
genotype/NN
call/JJ
rate/NN
below/IN
0.1/CD
,/,
a/DT
minor/JJ
allele/NN
frequency/NN
(/(
MAF/NN
)/)
greater/JJR
than/IN
0.01/CD
,/,
and/CC
no/DT
deviation/NN
from/IN
Hardy-Weinberg/JJ
equilibrium/NN
(/(
HWE/NN
)/)
(/(
p/NN
>/JJR
1/CD
×/NN
10-6/CD
)/)
./.
====================
To/TO
examine/VB
the/DT
population/NN
stratification/NN
,/,
multidimensional/JJ
scaling/VBG
analysis/NN
and/CC
principal/JJ
component/NN
analysis/NN
were/VBD
performed/VBN
using/VBG
44,724/CD
pruned/VBN
SNP/NN
markers/NNS
[/(
14/CD
]/)
./.
====================
Statistical/JJ
analysis/NN
====================
The/DT
orthostatic/JJ
BP/NN
changes/NNS
were/VBD
calculated/VBN
by/IN
deltaBP/NN
=/JJ
mean/NN
supine/NN
position/NN
BP/NN
-/:
standing/VBG
position/NN
BP/NN
./.
====================
Delta/NN
systolic/JJ
blood/NN
pressures/NNS
(/(
dtSBP/NN
)/)
,/,
delta/NN
diastolic/JJ
blood/NN
pressure/NN
(/(
dtDBP/NN
)/)
,/,
and/CC
OH/NN
cases/NNS
(/(
dtSBP/NN
≥/CD
20/CD
and/or/CC
dtDBP/NN
≥/CD
10/CD
[/(
16/CD
]/)
)/)
were/VBD
analyzed/VBN
by/IN
linear/JJ
or/CC
logistic/JJ
regression/NN
,/,
controlling/VBG
for/IN
covariates/VBZ
,/,
such/JJ
as/IN
age/NN
,/,
sex/NN
,/,
BMI/NNP
,/,
and/CC
systolic/JJ
BP/NN
./.
====================
Statistical/JJ
analyses/NNS
were/VBD
performed/VBN
using/VBG
PLINK/NN
version/NN
1.07/CD
,/,
using/VBG
default/JJ
options/NNS
[/(
17/CD
]/)
and/CC
SPSS/NN
version/NN
15.0/CD
(/(
SPSS/NN
Inc./NNP
,/,
Chicago/JJ
,/,
IL/NN
,/,
USA/NN
)/)
./.
====================
The/DT
GWAS/NN
were/VBD
conducted/VBN
for/IN
Ansan/NN
and/CC
Ansung/JJ
separately/RB
./.
====================
The/DT
Ansan/JJ
GWAS/NN
and/CC
Ansung/JJ
replication/NN
study/NN
results/VBZ
were/VBD
combined/VBN
by/IN
inverse-variance/NN
meta-analysis/NN
method/NN
,/,
assuming/VBG
fixed/JJ
effects/NNS
,/,
with/IN
Cochran/NN
's/POS
Q/NN
test/NN
used/VBN
to/TO
assess/VB
between-study/IN
heterogeneity/NN
[/(
18/CD
]/)
./.
====================
The/DT
selected/VBN
SNPs/NNS
had/VBD
a/DT
common/JJ
MAF/NN
(/(
>/JJR
0.05/CD
)/)
and/CC
the/DT
population/NN
heterogeneity/NN
(/(
p/NN
>/JJR
0.05/CD
)/)
./.
====================
The/DT
asymptotic/JJ
HWE/NN
tests/NNS
were/VBD
conducted/VBN
using/VBG
PLINK/NN
,/,
and/CC
all/DT
the/DT
reported/VBN
p-values/NNS
were/VBD
two-sided/VBN
./.
====================
Clinical/JJ
characteristics/NNS
====================
Table/JJ
1/CD
describes/VBZ
the/DT
clinical/JJ
characteristics/NNS
of/IN
OH/NN
case/NN
and/CC
control/JJ
subjects/NNS
in/IN
the/DT
Ansan/NN
and/CC
Ansung/JJ
cohorts/NNS
;/:
311/CD
participants/NNS
(/(
7.6/CD
%/NN
)/)
and/CC
496/CD
participants/NNS
(/(
14.3/CD
%/NN
)/)
were/VBD
found/VBN
to/TO
have/VB
OH/NN
in/IN
Ansan/JJ
and/CC
Ansung/JJ
,/,
respectively/RB
./.
====================
The/DT
gender/NN
distributions/NNS
of/IN
OH/NN
differed/VBD
significantly/RB
in/IN
both/DT
cohorts/NNS
,/,
and/CC
more/RBR
male/JJ
OH/NN
in/IN
Ansung/JJ
and/CC
less/RBR
male/JJ
OH/NN
in/IN
Ansan/NN
were/VBD
observed/VBN
./.
====================
The/DT
age/NN
of/IN
OH/NN
in/IN
Ansung/JJ
(/(
58.8/CD
±/CD
7.8/CD
years/NNS
)/)
was/VBD
older/JJR
than/IN
that/DT
in/IN
Ansan/NN
(/(
51.5/CD
±/CD
8.3/CD
years/NNS
)/)
,/,
reflecting/VBG
the/DT
higher/JJR
prevalence/NN
of/IN
OH/NN
in/IN
Ansung/JJ
./.
====================
The/DT
BMI/NN
was/VBD
significantly/RB
smaller/JJR
in/IN
Ansung/JJ
OH/NN
cases/NNS
than/IN
controls/NNS
,/,
but/CC
it/PRP
was/VBD
not/RB
significant/JJ
in/IN
Ansan/NN
./.
====================
While/IN
the/DT
mean/JJ
supine/NN
BP/NN
was/VBD
significantly/RB
higher/JJR
in/IN
OH/NN
than/IN
controls/NNS
,/,
the/DT
standing/NN
BP/NN
was/VBD
significantly/RB
lower/JJR
in/IN
OH/NN
than/IN
controls/NNS
./.
====================
Genome-wide/NN
association/NN
studies/NNS
====================
GWAS/NN
were/VBD
conducted/VBN
for/IN
each/DT
cohort/NN
,/,
and/CC
the/DT
target/NN
phenotypes/NNS
were/VBD
dtSBP/NN
,/,
dtDBP/NN
,/,
and/CC
OH/NN
./.
====================
The/DT
GWAS/NN
results/NNS
of/IN
each/DT
cohort/NN
were/VBD
combined/VBN
by/IN
meta-analyses/NNS
,/,
and/CC
quantile-quantile/JJ
plots/NNS
and/CC
Manhattan/JJ
plots/NNS
are/VBP
depicted/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
All/DT
detected/VBN
SNPs/NNS
are/VBP
described/VBN
in/IN
Table/JJ
2/CD
./.
====================
Five/CD
SNPs/NNS
for/IN
dtSBP/NN
trait/VBP
and/CC
three/CD
SNPs/NNS
for/IN
dtDBP/NN
trait/VBP
passed/VBN
our/PRP$
criteria/NNS
(/(
replicated/VBN
in/IN
both/DT
cohorts/NNS
[/(
Ansung/JJ
and/CC
Ansan/NN
]/)
and/CC
p/NN
</JJR
1/CD
×/NN
10-5/CD
)/)
,/,
but/CC
unfortunately/RB
,/,
the/DT
SNPs/NNS
of/IN
the/DT
OH/NN
case/NN
control/NN
GWAS/NN
did/VBD
not/RB
pass/VB
our/PRP$
p-value/NN
criteria/NNS
./.
====================
Among/IN
the/DT
significant/JJ
SNPs/NNS
,/,
four/CD
SNPs/NNS
(/(
rs6736587/NN
,/,
rs6756959/NN
,/,
rs6715049/NN
,/,
and/CC
rs17020502/NN
)/)
were/VBD
in/IN
the/DT
high/JJ
linkage/NN
disequilibrium/NN
status/NN
(/(
r2/NN
>/JJR
0.9/CD
)/)
and/CC
were/VBD
including/VBG
the/DT
most/JJS
significant/JJ
SNP/NN
,/,
rs6736587/NN
(/(
meta-analysis/NN
p-value/JJ
,/,
5.3/CD
×/CD
10-8/CD
)/)
./.
====================
The/DT
region/NN
of/IN
four/CD
SNPs/NNS
was/VBD
located/JJ
in/IN
the/DT
intergenic/JJ
region/NN
of/IN
chromosome/NN
2/CD
,/,
and/CC
the/DT
nearest/JJ
gene/NN
(/(
CTNNA2/NN
)/)
was/VBD
located/JJ
at/IN
1/CD
Mb/NN
of/IN
distance/NN
./.
====================
The/DT
remaining/VBG
SNPs/NNS
revealed/VBD
a/DT
suggestive/JJ
association/NN
(/(
p/NN
</JJR
1/CD
×/NN
10-5/CD
)/)
with/IN
dtSBP/NN
at/IN
rs7098785/NN
(/(
PIK3AP1/NN
intron/NN
)/)
and/CC
with/IN
dtDBP/NN
at/IN
rs6892553/NN
,/,
rs16887217/RB
,/,
and/CC
rs4959677/NN
,/,
which/WDT
were/VBD
located/JJ
in/IN
the/DT
ACTBL2/NN
3/CD
'/``
flanking/JJ
,/,
steroidogenic/JJ
acute/JJ
regulatory/JJ
protein/NN
(/(
STAR/NN
)/)
intron/NN
,/,
and/CC
intergenic/JJ
regions/NNS
(/(
chromosome/NN
6p/JJ
25.2/CD
)/)
,/,
respectively/RB
./.
====================
These/DT
normal/JJ
baro-reflex/JJ
responses/NNS
cause/VBP
an/DT
increase/NN
in/IN
heart/NN
rate/NN
and/CC
vascular/JJ
resistance/NN
,/,
restoring/VBG
normal/JJ
BP/NN
and/CC
cardiac/JJ
output/RB
[/(
1/CD
]/)
./.
====================
OH/NN
is/VBZ
the/DT
failure/NN
of/IN
the/DT
cardiovascular/JJ
reflexes/NNS
to/TO
maintain/VB
BP/NN
on/IN
standing/VBG
from/IN
a/DT
supine/NN
position/NN
[/(
2/CD
]/)
./.
====================
Also/RB
,/,
the/DT
frequency/NN
of/IN
OH/NN
in/IN
families/NNS
with/IN
a/DT
history/JJ
of/IN
essential/JJ
hypertension/NN
may/MD
be/VB
higher/JJR
than/IN
in/IN
the/DT
general/JJ
population/NN
[/(
4/CD
]/)
./.
====================
Therefore/RB
,/,
the/DT
identification/NN
of/IN
genetic/JJ
factor/NN
for/IN
orthostasis/NN
will/MD
help/VB
us/PRP
understand/VB
OH/NN
mechanisms/NNS
./.
====================
The/DT
signal/NN
plot/NN
for/IN
the/DT
most/JJS
significant/JJ
SNP/NN
(/(
rs6736587/NN
)/)
is/VBZ
depicted/VBN
in/IN
Fig/NN
./.
====================
2/CD
;/:
the/DT
region/NN
was/VBD
intergenic/JJ
and/CC
a/DT
functional/JJ
gene/NN
was/VBD
located/JJ
1/CD
Mbp/NN
upstream/RB
./.
====================
Interestingly/RB
,/,
this/DT
region/NN
is/VBZ
known/VBN
as/IN
the/DT
chromosome/NN
2p12-11.2/CD
deletion/NN
syndrome/NN
region/NN
,/,
and/CC
several/JJ
cases/NNS
report/VBP
mental/JJ
or/CC
psychomotor/NN
retardation/NN
[/(
19/CD
,/,
20/CD
]/)
./.
====================
There/EX
was/VBD
only/RB
one/CD
gene/NN
,/,
CTNNA2/NN
(/(
or/CC
known/VBN
as/IN
alpha-N-catenin/NN
)/)
,/,
around/IN
±1/CD
Mbp/JJ
./.
====================
CTNNA2/NN
is/VBZ
a/DT
linker/NN
between/IN
cadherin/NN
adhesion/NN
receptors/NNS
and/CC
the/DT
actin/NN
cytoskeleton/JJ
and/CC
is/VBZ
essential/JJ
for/IN
stabilizing/VBG
dendritic/JJ
spines/NNS
in/IN
rodent/JJ
hippocampal/JJ
neurons/NNS
[/(
21/CD
]/)
./.
====================
Although/IN
there/EX
is/VBZ
no/DT
report/NN
about/IN
function/NN
in/IN
BP/NN
regulation/NN
,/,
hippocampal/JJ
neurons/NNS
interact/VBP
primarily/RB
with/IN
the/DT
autonomic/JJ
nervous/JJ
system/NN
./.
====================
Therefore/RB
,/,
the/DT
CTNNA2/NN
gene/NN
may/MD
function/VB
in/IN
orthostatic/JJ
BP/NN
regulation/NN
./.
====================
Among/IN
the/DT
other/JJ
SNPs/NNS
,/,
rs7098785/NN
was/VBD
located/JJ
in/IN
the/DT
phosphoinositide-3-kinase/NN
adaptor/NN
protein/NN
1/CD
(/(
PIK3AP1/NN
)/)
gene/NN
./.
====================
PIK3AP1/NN
is/VBZ
involved/VBN
in/IN
B-cell/NN
development/NN
[/(
22/CD
]/)
./.
====================
Interestingly/RB
,/,
in/IN
silico/JJ
analyses/NNS
by/IN
the/DT
UCSC/NN
genome/NN
browser/JJR
(/(
http/NN
:/:
//genome.ucsc.edu//JJ
)/)
indicated/VBD
that/IN
the/DT
SNP/NN
was/VBD
located/JJ
in/IN
a/DT
DNase/NN
I/CD
hypersensitive/JJ
region/NN
and/CC
in/IN
the/DT
binding/VBG
site/NN
of/IN
transcription/NN
factors/NNS
(/(
MEF2C/NN
,/,
BATF/NN
,/,
MEF2A/NN
)/)
./.
====================
Therefore/RB
,/,
the/DT
rs7098785/NN
SNP/NN
might/MD
have/VB
a/DT
regulatory/JJ
function/NN
of/IN
PIK3AP1/NN
expression/NN
./.
====================
The/DT
remaining/VBG
three/CD
SNPs/NNS
of/IN
dtDBP/NN
were/VBD
located/JJ
in/IN
the/DT
ACTBL2/NN
(/(
beta-actin/NN
like/IN
protein/NN
2/CD
)/)
3/CD
'/``
flanking/JJ
region/NN
,/,
STAR/NN
intron/NN
,/,
and/CC
intergenic/JJ
region/NN
(/(
chromosome/NN
6p/NN
25.2/CD
)/)
./.
====================
The/DT
ACTBL2/NN
protein/NN
is/VBZ
involved/VBN
in/IN
various/JJ
types/NNS
of/IN
cell/NN
motility/NN
[/(
23/CD
]/)
,/,
and/CC
STAR/NN
is/VBZ
involved/VBN
in/IN
the/DT
regulation/NN
of/IN
steroid/NN
hormone/NN
synthesis/NN
[/(
24/CD
]/)
./.
====================
Our/PRP$
study/NN
was/VBD
the/DT
first/JJ
trial/JJ
to/TO
identify/VB
genetic/JJ
variants/NNS
for/IN
orthostatic/JJ
BP/NN
traits/VBZ
in/IN
Koreans/NNS
./.
====================
We/PRP
hope/VBP
that/DT
our/PRP$
finding/NN
could/MD
help/VB
us/PRP
understand/VB
the/DT
underlying/VBG
mechanism/NN
of/IN
orthostatic/JJ
BP/NN
changes/NNS
and/CC
related/JJ
diseases/NNS
./.
====================
Quantile-quantile/JJ
plots/NNS
and/CC
Manhattan/JJ
plots/NNS
of/IN
genomewide/NN
association/NN
studies/NNS
for/IN
delta/NN
systolic/JJ
blood/NN
pressure/NN
(/(
A/DT
,/,
D/NN
)/)
,/,
delta/NN
diastolic/JJ
blood/NN
pressure/NN
(/(
B/NN
,/,
E/NN
)/)
,/,
and/CC
orthostatic/JJ
hypotension/NN
(/(
C/NN
,/,
F/NN
)/)
./.
====================
Signal/NN
plot/NN
of/IN
the/DT
most/JJS
significant/JJ
association/NN
with/IN
delta/NN
systolic/JJ
blood/NN
pressure/NN
./.
====================
SNP/NN
,/,
single/JJ
nucleotide/NN
polymorphism/NN
./.
====================
Clinical/JJ
characteristics/NNS
of/IN
orthostatic/JJ
hypotension/NN
case/NN
controls/VBZ
in/IN
Ansan/NN
and/CC
Ansung/JJ
cohorts/NNS
phenotype/NN
====================
Significant/JJ
SNPs/NNS
of/IN
genomewide/NN
association/NN
study/NN
and/CC
replication/NN
results/VBZ
====================
